This amplicon-based SARS-CoV-2 NGS panel is designed for COVID-19 Coronavirus research and surveillance, enabling complete genome sequencing of the new SARS-CoV-2 virus responsible for the COVID-19 pandemic. This panel is specific for Illumina Sequencing platforms.
This is a highly multiplexed target enrichment panel covering the entire genome of SARS-CoV-2 virus (except for 92 bases at the ends). The panel enables complete genome sequencing and epidemiological studies of the new SARS-CoV-2 virus responsible for the COVID-19 pandemic. With CleanPlex technology, the entire genome of the virus can be amplified from RNA to sequence-ready libraries in 5.5 hours. Two versions of this the panel are available for two major sequencing platforms: Illumina and MGI. CleanPlex Technology allows the ease and flexibility to sequence samples for confident infectious disease surveillance and research.
- Significant Cost Savings
99% reduction in sequencing cost. Only 50K reads per sample required v.s. 10M reads required by many shotgun metagenomics sequencing methods.
- High Coverage of Target Regions
99% coverage of the entire SARS-CoV-2 genome
- Sensitive Detection
Can detect down to 1 copy with high confidence compared 3-5 copies by RT-qPCR (1)
- Fast, Streamlined Workflow
Generate sequencing-ready libraries in just 5.5 hours using a rapid, four-step protocol including RT step with minimal hands on time.
- Superb Performance
Prepare high-quality NGS libraries with excellent on-target performance using CleanPlex Technology to enable efficient use of sequencing reads. CleanPlex panels’ on-target rates are usually much higher than those of hybrid captured-based small target enrichment panels.
The CleanPlex SARS-CoV-2 Panel contains the CleanPlex Multiplex PCR Primers and CleanPlex Targeted Library Kit with RT components. CleanPlex Indexed PCR Primers for sample pooling and CleanMag Magnetic Beads for bead purification and size selection are ordered separately to complete the workflow from input RNA to sequencing-ready NGS libraries.